First-in-Human trial tests implant to stop Cancer's return after surgery
NCT ID NCT04619056
Summary
This first-in-human study tested the safety of a special drug-coated membrane placed in the surgical area immediately after removing a recurring or advanced abdominal soft tissue sarcoma. The goal was to see if leaving this slow-release chemotherapy implant where the tumor was could help prevent the cancer from coming back locally. The study involved 21 patients and focused on finding the highest safe dose of the drug (SN-38) for future research.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT SOFT TISSUE SARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fundación Jiménez Díaz
Madrid, 28040, Spain
-
Hospital General Universitario Gregorio Marañón
Madrid, 28007, Spain
-
Hospital Universitario Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital Universitario y Politécnico La Fe
Valencia, 46026, Spain
-
Hospital de la Santa Creu i Sant Pau
Barcelona, Catalonia, 08041, Spain
Conditions
Explore the condition pages connected to this study.